SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Madharry who wrote (38)10/10/2001 9:12:46 AM
From: Biomaven  Read Replies (1) of 146
 
Madharry,

Their latest 10-K discloses the following:

Securities and the related number of common shares not included in the diluted computation for the year ended December 31, 2000 that could potentially dilute basic earnings per share, if any, in the future are as follows:

Dilutive Potential
Common Shares *
------------------
<S> <C>
Preferred stock (see below)............................... 6,858,000
Options................................................... 2,115,000
Warrants.................................................. 1,531,000
Common stock--subject to repurchase....................... 179,000
----------
10,683,000
==========


* Includes weighted average shares for period prior to conversion and exercise.

The preferred stock automatically converted into common stock on a 1 for .36 basis and certain nonvested common stock automatically became vested upon completion of the initial public offering of the Company's common stock in August 2000.

So that 10.6MM number includes the preferred, which is now gone. I haven't looked at their S-1, which might have presented this differently.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext